Puma Biotech shares are trading at historical lows.
This can be attributed to subpar performance and direct competition from a newly approved drug.
However, Puma still has room to grow and the current valuation might be unwarranted.
Puma Biotechnology (PBYI) is a pharmaceutical company producing drugs used in cancer treatments. Their main product is Nerylinx, a compound used to treat breast cancer, specifically those that are HER-2 positive.